IO-INTERACTIVE
17.1.2024 15:01:33 CET | Business Wire | Press release
IO Interactive, the independent video game developer and publisher best known for the Hitman and Freedom Fighters franchises, announces today that Veronique Lallier will be joining IOI as its new Chief Development Officer. Operating globally across all studios and situated in Brighton which opened in July 2023, Veronique will be charged with overseeing IOI’s game development strategy and production.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116212318/en/
Veronique Lallier (Photo: IO Interactive)
"I'm excited to join IO Interactive, an iconic game studio with a 25-year legacy of maintaining high standards and creating globally recognized franchises. With exciting projects underway and new studios opening across Europe, I look forward to playing a role in IOI's continued growth and success," shared Veronique Lallier.
Veronique brings with her a wealth of experience in the gaming industry with prior roles in leading video game studios such as Hi-Rez Studios, serving as COO and Studio GM; Warner Bros. Interactive Entertainment as Vice President of Digital Publishing; NCSoft as Studio Managing Director but also Rockstar Games and Ubisoft.
“We are glad to welcome Veronique to IOI. She will bring immense experience, having assumed senior roles in household names in the gaming industry both in Eastern and Western studios. Her background in marketing, publishing, and production is a great blend and makes for a unique profile who will be a tremendous asset for our teams as we look to grow and diversify our IPs,” said Hakan Abrak, CEO of IO Interactive.
The team at the newly opened IOI Brighton studio has hit the ground running since last July and is fully integrated into the development process of the projects currently underway at IO Interactive. Adhering to IOI’s philosophy of working on any project from any studio, the Brighton team has already joined working on Project 007, the first James Bond origin story; Project Fantasy, an online fantasy RPG; and HITMAN World of Assassination.
Building upon the core team already in place, IOI’s ambition for its Brighton studio is to expand over the next year and welcome new talent from the exciting UK development scene with 100 positions now open in various roles. IOI is thus carrying on its organic growth which has been building up for the last few years, with the independent developer and publisher looking to bolster its teams.
With now five studios up and running in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton, IOI is gearing up to be in full force to deliver ambitious and innovative new IPs, after the great success brought about by the completion of the HITMAN trilogy.
Join the IO Interactive journey today and browse our open jobs on our website: www.ioi.dk/careers
ABOUT IO INTERACTIVE
IO Interactive is an independent videogame developer and publisher with studios in Copenhagen, Malmö, Barcelona, Istanbul, and Brighton. As the creative force behind some of the most talked-about multiplatform video games in the last two decades, IOI is dedicated to creating unforgettable characters and experiences using their award-winning proprietary Glacier technology.
IO Interactive will develop and publish the very first James Bond origin story with the working title Project 007 and is currently developing a new IP under the codename Project Fantasy. For more information, visit https://ioi.dk.
© 2024 IO Interactive A/S. IO Interactive and the IOI logo are registered trademarks of IO Interactive A/S.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116212318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom